March 28, 2008 - The 21st century will be a time of personalized care for patients with breast cancer where tools such as biomarkers, multi-gene assays and single-gene assays will help clinicians individualize treatment, according to Peter Ravdin, M.D., Ph.D., presenting at the The National Comprehensive Cancer Network’s (NCCN) 13th Annual Conference.
However, Dr. Ravdin cautioned, further validation is still necessary to confirm some of the predictive capacities of these tests.